GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001063218 | Oral cavity | OSCC | regulation of epithelial cell migration | 136/7305 | 292/18723 | 4.82e-03 | 1.92e-02 | 136 |
GO:00514969 | Oral cavity | OSCC | positive regulation of stress fiber assembly | 30/7305 | 52/18723 | 4.84e-03 | 1.92e-02 | 30 |
GO:00331972 | Oral cavity | OSCC | response to vitamin E | 9/7305 | 11/18723 | 4.85e-03 | 1.92e-02 | 9 |
GO:00364904 | Oral cavity | OSCC | regulation of translation in response to endoplasmic reticulum stress | 9/7305 | 11/18723 | 4.85e-03 | 1.92e-02 | 9 |
GO:19032654 | Oral cavity | OSCC | positive regulation of tumor necrosis factor-mediated signaling pathway | 9/7305 | 11/18723 | 4.85e-03 | 1.92e-02 | 9 |
GO:00310603 | Oral cavity | OSCC | regulation of histone methylation | 38/7305 | 69/18723 | 4.90e-03 | 1.94e-02 | 38 |
GO:003432916 | Oral cavity | OSCC | cell junction assembly | 190/7305 | 420/18723 | 4.99e-03 | 1.96e-02 | 190 |
GO:00447067 | Oral cavity | OSCC | multi-multicellular organism process | 105/7305 | 220/18723 | 5.05e-03 | 1.97e-02 | 105 |
GO:00713473 | Oral cavity | OSCC | cellular response to interleukin-1 | 58/7305 | 113/18723 | 5.14e-03 | 2.01e-02 | 58 |
GO:0000725 | Oral cavity | OSCC | recombinational repair | 70/7305 | 140/18723 | 5.22e-03 | 2.03e-02 | 70 |
GO:000268810 | Oral cavity | OSCC | regulation of leukocyte chemotaxis | 62/7305 | 122/18723 | 5.22e-03 | 2.03e-02 | 62 |
GO:005149220 | Oral cavity | OSCC | regulation of stress fiber assembly | 48/7305 | 91/18723 | 5.32e-03 | 2.07e-02 | 48 |
GO:00622087 | Oral cavity | OSCC | positive regulation of pattern recognition receptor signaling pathway | 26/7305 | 44/18723 | 5.49e-03 | 2.13e-02 | 26 |
GO:0000724 | Oral cavity | OSCC | double-strand break repair via homologous recombination | 69/7305 | 138/18723 | 5.52e-03 | 2.14e-02 | 69 |
GO:00486759 | Oral cavity | OSCC | axon extension | 61/7305 | 120/18723 | 5.52e-03 | 2.14e-02 | 61 |
GO:00109763 | Oral cavity | OSCC | positive regulation of neuron projection development | 80/7305 | 163/18723 | 5.54e-03 | 2.14e-02 | 80 |
GO:19021001 | Oral cavity | OSCC | negative regulation of metaphase/anaphase transition of cell cycle | 25/7305 | 42/18723 | 5.63e-03 | 2.17e-02 | 25 |
GO:000680915 | Oral cavity | OSCC | nitric oxide biosynthetic process | 41/7305 | 76/18723 | 5.78e-03 | 2.22e-02 | 41 |
GO:2000108 | Oral cavity | OSCC | positive regulation of leukocyte apoptotic process | 17/7305 | 26/18723 | 5.83e-03 | 2.23e-02 | 17 |
GO:00436244 | Oral cavity | OSCC | cellular protein complex disassembly | 68/7305 | 136/18723 | 5.84e-03 | 2.24e-02 | 68 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517114 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0513014 | Liver | NAFLD | Pathogenic Escherichia coli infection | 45/1043 | 197/8465 | 2.31e-05 | 6.88e-04 | 5.54e-04 | 45 |
hsa0481010 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa0517115 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0513015 | Liver | NAFLD | Pathogenic Escherichia coli infection | 45/1043 | 197/8465 | 2.31e-05 | 6.88e-04 | 5.54e-04 | 45 |
hsa0481011 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa0517122 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481021 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0513022 | Liver | Cirrhotic | Pathogenic Escherichia coli infection | 88/2530 | 197/8465 | 6.48e-06 | 6.24e-05 | 3.84e-05 | 88 |
hsa0517132 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481031 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0513032 | Liver | Cirrhotic | Pathogenic Escherichia coli infection | 88/2530 | 197/8465 | 6.48e-06 | 6.24e-05 | 3.84e-05 | 88 |
hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa0513042 | Liver | HCC | Pathogenic Escherichia coli infection | 129/4020 | 197/8465 | 2.02e-07 | 2.50e-06 | 1.39e-06 | 129 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0481041 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
F2 | SNV | Missense_Mutation | novel | c.1390N>T | p.Ala464Ser | p.A464S | P00734 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B6-A0RL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
F2 | SNV | Missense_Mutation | rs121918482 | c.1292N>A | p.Arg431His | p.R431H | P00734 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
F2 | SNV | Missense_Mutation | | c.448N>T | p.Ala150Ser | p.A150S | P00734 | protein_coding | tolerated(0.47) | benign(0.06) | TCGA-E2-A15S-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
F2 | insertion | In_Frame_Ins | novel | c.1074_1075insACCCAGCATGAGCTTTCCTGGGATTACTCATAT | p.Ser358_Tyr359insThrGlnHisGluLeuSerTrpAspTyrSerTyr | p.S358_Y359insTQHELSWDYSY | P00734 | protein_coding | | | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
F2 | deletion | Frame_Shift_Del | | c.1015_1025delNNNNNNNNNNN | p.Pro340GlufsTer55 | p.P340Efs*55 | P00734 | protein_coding | | | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
F2 | deletion | Frame_Shift_Del | novel | c.204delN | p.Glu69ArgfsTer52 | p.E69Rfs*52 | P00734 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
F2 | SNV | Missense_Mutation | rs144785536 | c.103C>T | p.Arg35Trp | p.R35W | P00734 | protein_coding | tolerated(0.11) | benign(0.093) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
F2 | SNV | Missense_Mutation | novel | c.1755N>T | p.Met585Ile | p.M585I | P00734 | protein_coding | tolerated(0.47) | benign(0.011) | TCGA-EK-A2RE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
F2 | SNV | Missense_Mutation | novel | c.225N>C | p.Glu75Asp | p.E75D | P00734 | protein_coding | deleterious(0.01) | probably_damaging(0.987) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
F2 | SNV | Missense_Mutation | rs775306348 | c.5C>T | p.Ala2Val | p.A2V | P00734 | protein_coding | tolerated_low_confidence(0.14) | benign(0.01) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | Anisindione | ANISINDIONE | |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | LEPIRUDIN | LEPIRUDIN | |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | ATryn antithrombin | | 24391399 |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | (-)-EPICATECHIN | (-)-EPICATECHIN | |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | hormonal contraceptives for systemic use | | 15208046,28750087,12069454,16769590 |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | Odiparcil | ODIPARCIL | |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | QUERCETIN | QUERCETIN | |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | AZD-0837 | ATECEGATRAN METOXIL | |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | Hirudin | | |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | inhibitor | 178102998 | DABIGATRAN | |